Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Cash from Financing Activities (2017 - 2025)

VYNE Therapeutics' Cash from Financing Activities history spans 9 years, with the latest figure at -$34000.0 for Q2 2025.

  • For Q2 2025, Cash from Financing Activities fell 1600.0% year-over-year to -$34000.0; the TTM value through Jun 2025 reached -$255000.0, down 100.31%, while the annual FY2025 figure was -$143000.0, 1.42% down from the prior year.
  • Cash from Financing Activities reached -$34000.0 in Q2 2025 per VYNE's latest filing, up from -$87000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $82.7 million in Q4 2023 to a low of -$33.6 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $6.9 million, with a median of -$30000.0 recorded in 2022.
  • The largest YoY upside for Cash from Financing Activities was 52402.14% in 2021 against a maximum downside of 41025.61% in 2021.
  • A 5-year view of Cash from Financing Activities shows it stood at -$38000.0 in 2021, then skyrocketed by 647.37% to $208000.0 in 2022, then soared by 39641.83% to $82.7 million in 2023, then crashed by 100.16% to -$132000.0 in 2024, then soared by 74.24% to -$34000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Cash from Financing Activities are -$34000.0 (Q2 2025), -$87000.0 (Q1 2025), and -$132000.0 (Q4 2024).